Skip to main content

Wound healing and local neuroendocrine regulation in the injured liver

  • Mohammad R. Ebrahimkhani (a1), Ahmed M. Elsharkawy (a1) and Derek A. Mann (a1)

The hepatic wound-healing response is a complex process involving many different cell types and factors. It leads to the formation of excessive matrix and a fibrotic scar, which ultimately disrupts proper functioning of the liver and establishes cirrhosis. Activated hepatic myofibroblasts, which are derived from cells such as hepatic stellate cells (HSCs), play a key role in this process. Upon chronic liver injury, there is an upregulation in the local neuroendocrine system and it has recently been demonstrated that activated HSCs express specific receptors and respond to different components of this system. Neuroendocrine factors and their receptors participate in a complex network that modulates liver inflammation and wound healing, and controls the development and progression of liver fibrosis. The first part of this review provides an overview of the molecular mechanisms governing hepatic wound healing. In the second section, we explore important components of the hepatic neuroendocrine system and their recently highlighted roles in HSC biology and hepatic fibrogenesis. We discuss the therapeutic interventions that are being developed for use in antifibrotic therapy.

Corresponding author
*Corresponding author: Prof. Derek A. Mann, Liver Group, Institute of Cellular Medicine, 4th Floor, Cookson Building, Medical School, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK. Tel: +44 191 2223851; Fax: +44 191 2225455; E-mail:
Hide All
1Racanelli V. and Rehermann B. (2006) The liver as an immunological organ. Hepatology 43 (Suppl 1), S54-S62
2Friedman S.L. (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275, 2247-2250
3Novo E. et al. (2007) Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells. Am J Pathol 170, 1942-1953
4Ramadori G. et al. (1992) The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is down regulated during cell growth and by transforming growth factor-beta. Biochem Biophys Res Commun 183, 739-742
5Xu J. et al. (2007) Characterization of a Putative Intrarenal Serotonergic System. Am J Physiol Renal Physiol 293, 1468-1475
6Bigliardi-Qi M. et al. (2006) Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 74, 174-185
7Kawamoto K. and Matsuda H. (2004) Nerve growth factor and wound healing. Prog Brain Res 146, 369-384
8Wynn T.A. (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117, 524-529
9Desmouliere A., Chaponnier C. and Gabbiani G. (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13, 7-12
10Meneghin A. and Hogaboam C.M. (2007) Infectious disease, the innate immune response, and fibrosis. J Clin Invest 117, 530-538
11Adzick N.S. et al. (1985) Comparison of fetal, newborn, and adult wound healing by histologic, enzyme-histochemical, and hydroxyproline determinations. J Pediatr Surg 20, 315-319
12Stramer B.M., Mori R. and Martin P. (2007) The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol 127, 1009-1017
13Kumagai K. et al. (1999) Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 162, 4212-4219
14Iredale J.P. (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117, 539-548
15McCawley L.J. and Martrisian L.M. (2001) Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 13, 534-540
16Elsharkawy A.M., Oakley F., Mann D.A. (2005) The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10, 927-939
17Mutsaers S.E. et al. (1997) Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 29, 5-17
18Parsonage G. et al. (2005) A stromal address code defined by fibroblasts. Trends Immunol 26, 150-156
19Sempowski G.D. et al. (1995) Fibroblasts heterogeneity in the healing wound. Wound Repair Regen 3, 120-131
20Forbes S.J. et al. (2004) A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126, 955-963
21Russo F.P. et al. (2006) The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130, 1807-1821
22Kisseleva T. et al. (2006) Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45, 429-438
23Kinnman N. and Housset C. (2002) Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 7, 496-503
24Knittel T. et al. (1999) Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117, 1205-1221
25Zeisberg M. et al. (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282, 23337-23347
26Diaz R. et al. (2008) Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum Pathol 39, 102-115
27Robertson H. et al. (2007) Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 45, 977-981
28Kaimori A. et al. (2007) Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282, 22089-22101
29Tuchweber B. et al. (1996) Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest 74, 265-278
30Tang L. at al. (1994) Phenotypic change in portal fibroblasts in biliary fibrosis. Liver 14, 76-82
31Chi H. and Flavell R.A. (2007) Immunology: sensing the enemy within. Nature 448, 423-424
32Canbay A., Friedman S. and Gores G.J. (2004) Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39, 273-278
33Watanabe A. et al. (2007) Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46, 1509-1518
34Maher J. J. (1999) Leukocytes as modulators of stellate cell activation. Alcohol Clin Exp Res 23, 917-921
35Urtasun R. and Nieto N. (2007) Hepatic stellate cells and oxidative stress. Rev Esp Enferm Dig 99, 223-230
36Georges P.C. et al. (2007) Increased Stiffness of the Rat Liver Precedes Matrix Deposition: Implications for Fibrosis. Am J Physiol Gastrointest Liver Physiol 293, 1147-1154
37Paik Y.H. et al. (2003) Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37, 1043-1055
38Canbay A. et al. (2004) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308, 1191-1196
39Canbay A. et al. (2003) Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83, 655-663
40Seki E. et al. (2007) TLR4 enhances TGF-b signalling and hepatic fibrosis. Nat Med 13, 1324-1332
41Winau F. et al. (2007) Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26, 117-129
42Thurman R. G. (1998) Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275, G605-G611
43Liu C. et al. (2003) Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 278, 11721-11728
44Meyer D.H., Bachem M.G. and Gressner A.M. (1990) Transformed fat storing cells inhibit the proliferation of cultured hepatocytes by secretion of transforming growth factor beta. J Hepatol 11, 86-91
45Bataller R. et al. (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112, 1383-1394
46Bataller R. et al. (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118, 1149-1156
47Pinzani M. et al. (1995) Transforming growth factor-beta 1 regulates platelet-derived growth factor receptor beta subunit in human liver fat-storing cells. Hepatology 21, 232-239
48Sprenger H. et al. (1999) Differential expression of monocyte chemotactic protein-1 (MCP-1) in transforming rat hepatic stellate cells. J Hepatol 30, 88-94
49Marra F. et al. (1999) Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29, 140-148
50Ankoma-Sey V. et al. (1998) Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 17, 115-121
51Nieto N. (2006) Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology 44, 1487-1501
52Murphy F.R. et al. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277, 11069-11076
53Zhou X. et al. (2004) Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 279, 23996-24006
54Benyon R.C. and Arthur M.J. (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21, 373-384
55Alvaro D. et al. (2007) Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 132, 415-431
56Roskams T. et al. (2004) Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol 280, 910-923
57Roskams T . et al. (1990) Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 137, 1019-1025
58Roskams T. and Desmet V. (1997) Parathyroid-hormone-related peptides: a new class of multifunctional proteins. Am J Pathol 150, 779-785
59Marzioni M. et al. (2005) Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 128, 121-137
60Mosca A. et al. (2004) Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer. Dig Liver Dis (Suppl 1) 36, S60-S67
61Marzioni M., Fava G. and Benedetti A. (2006) Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol 12, 3471-3480
62Bosman F.T. (1997) Neuroendocrine cells in non-endocrine tumors: what does it mean? Verh Dtsch Ges Pathol 81, 62-72
63di Sant'Agnese P.A. and Cockett A.T. (1996) Neuroendocrine differentiation in prostatic malignancy. Cancer 78, 357-361
64Amorino G.P. and Parsons S.J. (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14, 287-300
65Walker G.E. et al. (2006) Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene 25, 1943-1954
66Nesland J.M. et al. (1988) Neuroendocrine differentiation in breast lesions. Pathol Res Pract 183, 214-221
67Eren F., Celikel C. and Güllüoğlu B. (2004) Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53. Pathol Oncol Res 10, 47-51
68Atasoy P. et al. (2003) Neuroendocrine differentiation in colorectal carcinomas: assessing its prognostic significance. Tumori 89, 49-53
69DeMorrow S. et al. (2007) Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 282, 13098-13113
70Chang K.T. et al. (2005) Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. Am J Physiol Lung Cell Mol Physiol 289, L438-445
71Dvorak H.F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315, 1650-1659
72Lin W.W. and Karin M. (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117, 1175-1183
73Elsharkawy A.M. and Mann D.A. (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590-597
74Ruddell R.G. et al. (2006) A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 169, 861-876
75Ebrahimkhani M.R. et al. (2006) Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 55, 1606-1616
76Yang Y.Y. et al. (2007) Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. Clin Sci (Lond) 112, 533-542
77Micera A. et al. The pro-fibrogenic effect of nerve growth factor on conjunctival fibroblasts is mediated by transforming growth factor-beta. Clin Exp Allergy 35, 650-656
78Libbrecht L. and Roskams T. (2002) Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 13, 389-396
79Roskams T. et al. (1991) Cells with neuroendocrine features in regenerating human liver. APMIS 23, 32-39
80Geerts A. (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21, 311-335
81Cassiman D. et al. (1999) Synaptophysin: A novel marker for human and rat hepatic stellate cells. Am J Pathol 155, 1831-1839
82Schurmann G. et al. (1990) Chromogranin A, neuron-specific enolase and synaptophysin as neuroendocrine cell markers in the diagnosis of tumours of the gastro-entero-pancreatic system. Eur J Surg Oncol 16, 298-303
83Cassiman D. et al. (2001) Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology 33, 148-158
84Haley K.J. et al. (1998) Tumor necrosis factor induces neuroendocrine differentiation in small cell lung cancer cell lines. Am J Physiol 275, L311-321
85Alvaro D., Gigliozzi A. and Attili A.F. (2000) Regulation and deregulation of cholangiocyte proliferation. J Hepatol 33, 333-340
86Lazaridis K.N., Strazzabosco M. and LaRusso N.F. (2004) The cholangiopathies: disorders of biliary epithelia. Gastroenterology 127, 1565-1577
87Qiu Y., Ravi L. and Kung H.J. (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393, 83-85
88Qiu Y. et al. (1998) Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95, 3644-3649
89Gigliozzi A. et al. (2004) Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology 127, 1198-1209
90Oakley F. et al. (2003) Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol 163, 1849-1858
91Passino M.A. et al. (2007) Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 315, 1853–1856
92Micera A. et al. (2001) Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 98, 6162-6167
93Micera A. et al. (2007) Nerve growth factor and tissue repair remodeling: trkA(NGFR) and p75(NTR), two receptors one fate. Cytokine Growth Factor Rev 18, 245-256
94Gershon M.D. and Tack J. (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132, 397-414
95Lesurtel M. et al. (2006) Platelet-derived serotonin mediates liver regeneration. Science 312, 104-107
96Li T. et al. (2006) Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells. Hepatobiliary Pancreat Dis Int 5, 96-100
97Mani A.R. et al. (2006) Endogenous opioids and liver disease. Scand J Gastroenterol 41, 1-11
98Thornton J.R. and Losowsky M.S. (1988) Opioid peptides and primary biliary cirrhosis. Br Med J 297, 1501-1504
99Bergasa N.V. et al. (1995) Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 68, G346-354
100Swain M.G. et al. (1992) Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 103, 630-635
101Marzioni M. et al. (2007) Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 46, 583-586
102De Minicis S. et al. (2008) Role Of Endogenous Opioids In Modulating HSC Activity In Vitro And Liver Fibrosis In Vivo. Gut 57, 352-364
103Centonze D. et al. (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28, 180-187
104Woods S.C. (2008) Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med (Suppl 1) 120, S19-S25
105Siegmund S.V. et al. (2005) Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41, 1085-1095
106Julien B. et al. (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742-755
107Siegmund S.V. et al. (2007) The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 21, 2798-2806
108Hézode C. et al. (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42, 63-71
109Teixeira-Clerc F. et al. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12, 671-676
110Kunos G. et al. (2006) Cannabinoids hurt, heal in cirrhosis. Nat Med 12, 608-610
111Marzioni M. et al. (2006) Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 130, 1831-1847
112Oo Y.H. and Neuberger J. (2004) Options for treatment of primary biliary cirrhosis. Drugs 64, 2261-2271
113Johnson B.A. (2008) Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 75, 34-56
114Lillo J.L. (2007) The endocannabinoid system as a novel approach for managing obesity. J Am Osteopath Assoc (Suppl 2) 107, S12-S20
115Iwakiri Y. and Groszmann R.J.The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology (Suppl 1) 43, S121-S131
116Gary-Bobo M. et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46, 122-129
117Nocito A. et al. (2007) Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133, 608-618
Iredale J.P. (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117, 539-548
Friedman S.L. and Bansal M.B. (2006) Reversal of hepatic fibrosis – fact or fantasy? Hepatology 43, S82-S88
Weiskirchen R. and Gressner A.M. (2005) Isolation and culture of hepatic stellate cells. Methods Mol Med 117, 99-113
Mann J. et al. (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14, 275-285

The British Liver Trust website provides various resources for both patients and health professionals and includes links to other websites of interest:

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 3
Total number of PDF views: 12 *
Loading metrics...

Abstract views

Total abstract views: 103 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th November 2017. This data will be updated every 24 hours.